Jaguar Health Inc (JAGX) — Titan Protect Analysis

JAGX

Jaguar Health Inc

Healthcare · ·

$2.80

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.54

Based on estimated future earnings — lower means cheaper

Rev Growth

+815.6%

Year-over-year revenue change

Profit Margin

-115.4%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$262.50

+9275% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Jaguar Health Inc

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief

https://jaguar.health

Country: United States Employees: 47 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-1.691

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.2107

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.972

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-97.1%

Historical annualised return based on price data

Max Drawdown

-99.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.03

Very low correlation to market moves

52W High

$144.90

98% below the year high

52W Low

$2.53

11% above the year low

Avg Volume

63,418

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-695.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

85.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

50.2%

Profit from core operations before interest and tax

Free Cash Flow

$-2,085,375

Negative — the business is spending more than it generates

Revenue (TTM)

$30M

Total revenue over the last 12 months

Net Income

$-50,126,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$262.50

Target Median

$262.50

Target Low

$262.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go